Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:IMGONYSE:PBHNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$34.36+2.1%$33.61$29.31▼$61.38$4.02B0.591.52 million shs1.31 million shsIMGOImago BioSciences$36.01$35.96$11.56▼$36.09$1.22B2.82171,367 shsN/APBHPrestige Consumer Healthcare$80.14-0.2%$84.16$64.94▼$90.04$3.97B0.43305,577 shs562,850 shsRYTMRhythm Pharmaceuticals$66.92+2.3%$62.63$40.46▼$69.89$4.16B2.26555,926 shs963,104 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+1.82%+0.72%+8.94%-16.42%-38.50%IMGOImago BioSciences0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare+0.54%-5.26%-6.42%-6.91%+18.59%RYTMRhythm Pharmaceuticals+3.56%+2.80%+6.65%+25.94%+53.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics4.2793 of 5 stars4.52.00.04.62.30.80.0IMGOImago BioSciencesN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare4.2153 of 5 stars2.34.00.03.53.01.71.9RYTMRhythm Pharmaceuticals3.9022 of 5 stars3.52.00.04.31.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.93Moderate Buy$70.92106.41% UpsideIMGOImago BioSciences 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3316.46% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$77.3115.52% UpsideCurrent Analyst Ratings BreakdownLatest IMGO, PBH, CYTK, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$84.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/7/2025CYTKCytokineticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M222.18N/AN/A($1.15) per share-29.88IMGOImago BioSciencesN/AN/AN/AN/A$6.40 per shareN/APBHPrestige Consumer Healthcare$1.14B3.48$5.20 per share15.41$37.04 per share2.16RYTMRhythm Pharmaceuticals$130.13M32.72N/AN/A$0.35 per share191.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$589.53M-$5.290.00N/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)IMGOImago BioSciences-$42.31M-$1.84N/AN/AN/AN/A-31.85%-30.07%N/APBHPrestige Consumer Healthcare$214.60M$4.2917.7316.842.4118.86%12.87%6.78%8/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.810.00N/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)Latest IMGO, PBH, CYTK, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AIMGOImago BioSciencesN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A5.995.99IMGOImago BioSciencesN/A13.1513.16PBHPrestige Consumer Healthcare0.554.202.82RYTMRhythm PharmaceuticalsN/A3.303.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AIMGOImago BioSciences91.53%PBHPrestige Consumer Healthcare99.95%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%IMGOImago BioSciences14.90%PBHPrestige Consumer Healthcare1.60%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.43 million116.20 millionOptionableIMGOImago BioSciences2733.82 million28.78 millionNot OptionablePBHPrestige Consumer Healthcare54049.42 million48.62 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableIMGO, PBH, CYTK, and RYTM HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals Inc News (RYTM) - Investing.com2 hours ago | investing.comAdcock, Chiefs blank Rhythm to win 5th straightJuly 1 at 6:12 AM | wpsdlocal6.comWNPSL: Bristol Rhythm fall on the road, close out season with two home games this weekJune 30 at 4:05 AM | heraldcourier.comHThe UniverSoul Circus brings its 'Rhythm of the World' tour to National HarborJune 30 at 4:05 AM | wusa9.comWOf Wood, Worship And Wonder: Rhythm Wagholikar On The Rath Yatra TraditionJune 28, 2025 | msn.comRhythm & Food community BBQJune 28, 2025 | kxnet.comKRhythm & Roots unveils artist schedule, puts single-day tickets on saleJune 28, 2025 | heraldcourier.comHRhythm & Rally offer pickleball for Neurodivergent kidsJune 28, 2025 | 41nbc.com4Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Market Outperform Rating from JMP SecuritiesJune 28, 2025 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (RYTM) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comRhythm Pharmaceuticals: Growth Is Expected To Go ParabolicJune 27, 2025 | seekingalpha.comRhythm and Blues ShowJune 27, 2025 | deltanews.tvDRhythm Pharmaceuticals Announces Late-Breaking Abstracts for ENDO 2025 Featuring Pivotal Phase 3 and Phase 2 Trial Results on Acquired Hypothalamic Obesity - NasdaqJune 27, 2025 | nasdaq.comRhythm Pharmaceuticals' (RYTM) "Market Outperform" Rating Reiterated at JMP SecuritiesJune 26, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025June 25, 2025 | finanznachrichten.deRhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025June 25, 2025 | globenewswire.comAvior Wealth Management LLC Invests $243,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)June 24, 2025 | marketbeat.com22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A.June 18, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)June 18, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)June 18, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 2,069 Shares of StockJune 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMGO, PBH, CYTK, and RYTM Company DescriptionsCytokinetics NASDAQ:CYTK$34.36 +0.72 (+2.14%) Closing price 04:00 PM EasternExtended Trading$34.76 +0.40 (+1.15%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Imago BioSciences NASDAQ:IMGOImago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Prestige Consumer Healthcare NYSE:PBH$80.14 -0.18 (-0.22%) Closing price 03:59 PM EasternExtended Trading$80.18 +0.04 (+0.05%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Rhythm Pharmaceuticals NASDAQ:RYTM$66.92 +1.48 (+2.26%) Closing price 04:00 PM EasternExtended Trading$68.41 +1.49 (+2.23%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
